Donor cell engraftment
| Group . | N . | H-2Dd−/b+ (%) . |
|---|---|---|
| Allogeneic BMT → WHI-P131 | 4 | 96.3 ± 1.1 |
| Allogeneic BMT + BCL-1 → WHI-P131 | 4 | 95.3 ± 0.8 |
| Allogeneic BMT + BCL-1 → MTX | 5 | 93.2 ± 2.6 |
| Allogeneic BMT + BCL-1 → WHI-P131 + MTX | 7 | 95.6 ± 1.0 |
| Syngeneic BMT | 5 | 0.0 ± 0.0 |
| Group . | N . | H-2Dd−/b+ (%) . |
|---|---|---|
| Allogeneic BMT → WHI-P131 | 4 | 96.3 ± 1.1 |
| Allogeneic BMT + BCL-1 → WHI-P131 | 4 | 95.3 ± 0.8 |
| Allogeneic BMT + BCL-1 → MTX | 5 | 93.2 ± 2.6 |
| Allogeneic BMT + BCL-1 → WHI-P131 + MTX | 7 | 95.6 ± 1.0 |
| Syngeneic BMT | 5 | 0.0 ± 0.0 |
Splenocytes of long-term survivors (> 60 days after BMT/BCL-1 injection), WHI-P131-, MTX-, and WHI-P131 + MTX-treated F1 recipients of allogeneic (B6) BM/S grafts and BCL-1 injections were analyzed by flow cytometry for engraftment. Syngeneic (F1 to F1) BM/S recipients are presented as controls. Data are presented as mean ± SEM values for the percentage of H-2Dd−/b+ donor cells.